Risk of Bleeding With Dabigatran in Atrial Fibrillation
Inmaculada Hernandez, Seo Hyon Baik, Antonio Pinera, Yuting Zhang
JAMA INTERNAL MEDICINE | AMER MEDICAL ASSOC | Published : 2015
IMPORTANCE: It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice. OBJECTIVE: To compare the risk of bleeding associated with dabigatran and warfarin using Medicare data. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, we used pharmacy and medical claims in 2010 to 2011 from a 5% random sample of Medicare beneficiaries. We identified participants as those newly diagnosed as having atrial fibrillation from October 1, 2010, through October 31, 2011, and who initiated dabigatran or warfarin treatment within 60 days of initial diagnosis. We followed up patients until disconti..View full abstract
Awarded by Commonwealth Foundation and Agency for Healthcare Research and Quality
This study was supported by grant RO1 HSO18657 from the Commonwealth Foundation and Agency for Healthcare Research and Quality (Dr Zhang).